Hematological Indices in Portal Hypertension: Cirrhosis versus Noncirrhotic Portal Hypertension

被引:6
|
作者
Sahin, Abdurrahman [1 ]
Artas, Hakan [2 ]
Tunc, Nurettin [1 ]
Yalniz, Mehmet [1 ]
Bahcecioglu, Ibrahim Halil [1 ]
机构
[1] Firat Univ, Sch Med, Dept Internal Med, Div Gastroenterol, TR-23200 Elazig, Turkey
[2] Firat Univ, Sch Med, Dept Radiol, TR-23200 Elazig, Turkey
来源
JOURNAL OF CLINICAL MEDICINE | 2018年 / 7卷 / 08期
关键词
hematological indices; portal hypertension; cirrhosis; noncirrhotic portal hypertension; neutrophil to lymphocyte ratio; TO-LYMPHOCYTE RATIO; VENOUS-PRESSURE GRADIENT; LIVER-CIRRHOSIS; HYPERSPLENISM; MANAGEMENT; DIAGNOSIS; PREVALENCE;
D O I
10.3390/jcm7080196
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Portal hypertension (PHT) leads to several alterations on hematological indices (HI). The aim of the study is to investigate the differences in HI between cirrhotic subjects and subjects who have noncirrhotic PHT (NCPHT). This retrospective study included 328 patients with PHT (239 cirrhosis and 89 NCPHT). Demographic and clinical features, endoscopic and radiological findings, and HI including neutrophil to lymphocyte ratio (NLR) at the time of PHT diagnosis were recorded. Severity of cirrhosis was assessed according to the Child-Turcotte-Pugh (CTP) classification and Model for End-Stage Liver Disease (MELD) scores. Hematological abnormalities were found in 92.5% of cirrhotic patients and in 55.1% of patients with NCPHT (p < 0.001). While thrombocytopenia was the most common HI in patients with cirrhosis, anemia was the most prevalent HI in NCPHT group. In the cirrhotic group, the NLR was the only parameter to differentiate each CTP group from two others. The NLR value increased with the severity of cirrhosis (2.28 +/- 0.14 in CTP-A, 2.85 +/- 0.19 in CTP-B and 3.26 +/- 0.37 in CTP-C). The AUROC of NLR was 0.692 for differentiating compensated cirrhotic patients from decompensated. Hematological abnormalities are more prevalent and more severe in cirrhotic patients compared to patients with NCPHT. NLR may be used to assess the severity of cirrhosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Hyperreactive malarial syndrome with noncirrhotic portal hypertension
    Acharya, Sourya
    Shukla, Samarth
    Mahajan, S. N.
    Diwan, S. K.
    Chaudhary, Karan
    ANNALS OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2010, 3 (02) : 75 - 77
  • [32] IGA NEPHROPATHY IN NONCIRRHOTIC PORTAL-HYPERTENSION
    BABBS, C
    WARNES, TW
    TORRANCE, HB
    BALLARDIE, FW
    GUT, 1991, 32 (02) : 225 - 226
  • [33] Noncirrhotic portal hypertension in a child with velocardiofacial syndrome
    Seaver, Laurie H.
    Brumblay, Janet M.
    Wilson, Claire M.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2007, 143A (21) : 2623 - 2624
  • [34] Minimal hepatic encephalopathy in noncirrhotic portal hypertension
    Mohan, Pazhanivel
    Venkataraman, Jayanthi
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (02) : 194 - 195
  • [35] Noncirrhotic Portal Hypertension Current and Emerging Perspectives
    Khanna, Rajeev
    Sarin, Shiv Kumar
    CLINICS IN LIVER DISEASE, 2019, 23 (04) : 781 - +
  • [36] Idiopathic noncirrhotic portal hypertension: current perspectives
    Riggio, Oliviero
    Gioia, Stefania
    Pentassuglio, Ilaria
    Nicoletti, Valeria
    Valente, Michele
    d'Amati, Giulia
    HEPATIC MEDICINE-EVIDENCE AND RESEARCH, 2016, 8 : 81 - 88
  • [37] Noncirrhotic portal hypertension in a young alcoholic male
    Al-Skaf, N
    O'Brien, JJ
    Purdy, RS
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S186 - S186
  • [38] A Rare Cause of Noncirrhotic Intrahepatic Portal Hypertension
    Chugh, Priyanka
    Park, James S.
    Hajdu, Cristina H.
    GASTROENTEROLOGY, 2014, 147 (03) : E7 - E9
  • [39] Effect of somatostatin versus octreotide on portal haemodynamics in patients with cirrhosis and portal hypertension
    Yang, JF
    Wu, XJ
    Li, JS
    Cao, JM
    Han, JM
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (01) : 53 - 57
  • [40] β-blockers for cirrhosis and portal hypertension
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (06): : 422 - 422